Recently, Wyeth Pharmaceuticals and Catalyst Biosciences, Inc. announced that they have formed an exclusive worldwide collaboration to develop factor VIIa (FVIIa) products to treat hemophilia and other bleeding conditions. According to the agreement, Wyeth will support the discovery, research and preclinical development by Catalyst of FVIIa products, including CB 813, Catalyst’s investigational drug candidate.

“We have been impressed by the caliber of Catalyst’s therapeutic protein engineering skills used in the Factor VIIa program and the lead candidate CB 813,” said Mikael Dolsten, MD, PhD, President, Wyeth Research. “We look forward to a highly productive collaboration.”

“We are thrilled to join forces with Wyeth, a biopharmaceutical company at the forefront of both hemophilia treatment and the development and commercialization of biologic therapies,” says Nassim Usman, PhD, Chief Executive Officer of Catalyst Biosciences. 

Source: Wyeth news release dated June 30, 2009